Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Cesar, Carina ^a   Shepherd, Bryan E ^b   Krolewiecki, Alejandro J ^a   Fink, Valeria I ^a   Schechter, Mauro ^c   Tuboi, Suely H ^c   Wolff, Marcelo ^d   Pape, Jean W ^e   Leger, Paul ^e   Padgett, Denis ^f   Madero, Juan Sierra ^g   Gotuzzo, Eduardo ^h   Sued, Omar ^a   Mcgowan, Catherine C ^b   Masys, Daniel R ^b   Cahn, Pedro E ^a  

^a FUNDACIÓN HUÉSPED   (Argentina)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF CHILE   (Chile)

^e Department of Adolescent Medicine   (Haïti)

^f NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^g INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^h INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARGENTINA; ARTICLE; BLOOD TOXICITY; BRAZIL; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CENTRAL AMERICA; CENTRAL NERVOUS SYSTEM DISEASE; CHILE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG ERUPTION; DRUG FATALITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GEOGRAPHIC DISTRIBUTION; HAITI; HEALTH HAZARD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HONDURAS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEXICO; PERU; PROBABILITY; RISK ASSESSMENT; RISK FACTOR; SKIN DISEASE; SOUTH AND CENTRAL AMERICA; TREATMENT DURATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LATIN AMERICA; MALE; SURVIVAL ANALYSIS; WEST INDIES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77955187276     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010490     Document Type: Article

References (41)

1. UNAIDS (2007) AIDS epidemic update. Available: http://www.unaids.org/en/HIV_data/2007EpiUpdate/default.asp. Accessed 2009, Sep 18.
2. Chequer P, Cuchi P, Mazin R, Garcia Calleja JM (2002) Access to antiretroviral treatment in Latin American countries and the Caribbean. Aids 16 Suppl 3: S50-57.
3. WHO (2008) Towards Universal Access Progress Report. Scaling up priority HIV/AIDS interventions in the health sector. Available: http://www.who.int/hiv/pub/2008progressreport/en. Accessed 2009, Sep 18.
4. Louis C, Ivers LC, Smith Fawzi MC, Freedberg KA, Castro A (2007) Late presentation for HIV care in central Haiti: factors limiting access to care. AIDS Care 19: 487-491.
5. Wolff MJ, Beltran CJ, Vasquez P, Ayala MX, Valenzuela M, et al. (2005) The Chilean AIDS cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country-organization and preliminary results. J Acquir Immune Defic Syndr 40: 551-557.
6. Souza-Jr PR, Szwarcwald CL, Castilho EA (2007) Delay in introducing antiretroviral therapy in patients infected by HIV in Brazil, 2003-2006. Clinics 62: 579-584.
7. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, et al. (2008) Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 13: 870-879.
8. Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewiecki A, et al. (2009) Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1- Infected Patients in 7 Sites Throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 51: 615-623.
9. Park WB, Choe PG, Kim SH, Jo JH, Bang JH, et al. (2007) Early modification of initial HAART regimen associated with poor clinical outcome in HIV patients. AIDS Res Hum Retroviruses 23: 794-800.
10. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, et al. (2000) Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. Aids 14: 499-507.
11. Dorrucci M, Pezzotti P, Grisorio B, Minardi C, Muro MS, et al. (2001) Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. Aids 15: 1733-1736.
12. Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, et al. (2006) Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 41: 53-58.
13. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, et al. (2001) Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. Aids 15: 185-194.
14. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P (2003) Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 34: 407-414.
15. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, et al. (2010) Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 170: 57-65.
16. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, et al. (2007) Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 12: 753-760.
17. Medeiros R, Diaz RS, Filho AC (2002) Estimating the length of the first antiretroviral therapy regiment durability in Sao Paulo, Brazil. Braz J Infect Dis 6: 298-304.
18. Padua CA, Cesar CC, Bonolo PF, Acurcio FA, Guimaraes MD (2006) High incidence of adverse reactions to initial antiretroviral therapy in Brazil. Braz J Med Biol Res 39: 495-505.
19. Padua CA, Cesar CC, Bonolo PF, Acurcio FA, Guimaraes MD (2007) Selfreported adverse reactions among patients initiating antiretroviral therapy in Brazil. Braz J Infect Dis 11: 20-26.
20. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 2325-2334.
21. Echevarria Zarate J, Lopez de Castilla Koster D, Iglesias Quilca D, Seas Ramos C, González Lagos E, et al. (2007) Efecto de la terapia antiretroviral de gran actividad (TARGA) en pacientes enrolados en un Hospital Público en Lima-Perú. Rev Med Hered [online] 18: 184-191.
22. Astuvilca J, Arce-Villavicencio Y, Sotelo R, Quispe J, Guillen R, et al. (2007) Incidencia y factores asociados con las reacciones adversas del tratamiento antirretroviral inicial en pacientes con VIH. Rev perú med exp salud publica [online] 24: 218-224.
23. Soria EA, Cadile II, Allende LR, Kremer LE (2008) Pharmacoepidemiological approach to the predisposing factors for highly active antiretroviral therapy failure in an HIV-positive cohort from Cordoba City (Argentina) 1995-2005. Int J STD AIDS 19: 335-338.
24. McGowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, et al. (2007) Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol 36: 969-976.
25. Comité Técnico Asesor de la Dirección de Sida y ETS del Ministerio de Salud de la Nación Argentina (2007) Recomendaciones para el tratamiento antirretroviral. Available: http://www.msal.gov.ar/sida/pdf/recomendacionestratamiento- antirretroviral.pdf. Accessed 2009, Sep 18.
26. Sociedad Argentina de Infectologia (2007) Recomendaciones para el seguimiento y tratamiento de la infeccion por HIV. Available: http://www.sadi.org. ar/files/HIV2007.pdf. Accessed 2009, Sep 18.
27. Ministério da Saúde, Secretaria de Vigilância em Saúde, Programa Nacional de DST e AIDS. (2008) Recomendações para Terapia Anti-retroviral em Adultos Infectados pelo HIV 2008. Available: http://www.aids.gov.br/ data/documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36- 1903553A3174%7D/%7B762E0EBF-A859-4779-8A92-704EB1F3B290%7D/ consensoAdulto005c_2008montado.pdf. Accessed 2009, Sep 18.
28. Ministerio de Salud. Chile. Guía Clínica Síndrome de la Inmunodeficiencia Adquirida. VIH/SIDA. 1st Ed. Santiago: Minsal, Available: http://www. redsalud.gov.cl/archivos/guiasges/vihsidaR_Mayo10.pdf. Accessed 2009, Sep 18.
29. Guía de manejo antirretroviral de las personas con VIH. Cuarta Edicion. México 2008. Available: http://www.censida.salud.gob.mx/interior/atencion. html. Accessed 2009, Sep 18.
30. WHO (2006) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. - 2006 rev. Available: http:// www.who.int/entity/hiv/pub/guidelines/artadultguidelines.pdf. Accessed 2009, Sep 18.
31. Shafer JL (1997) Analysis of Incomplete Multivariate Data. London: Chapman & Hall.
32. Harrell FEJ (2001) Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer.
33. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
34. Smith-Warner SA, Spiegelman D, Ritz J, Albanes D, Beeson WL, Bernstein L, et al. (2006) Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol 163: 1053-1064.
35. Hart E, Curtis H, Wilkins E, Johnson M (2007) National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients. HIV Med 8: 186-191.
36. Park-Wyllie LY, Scalera A, Tseng A, Rourke S (2002) High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: missed opportunities for adherence support? Aids 16: 1084-1086.
37. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P (2002) Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. Aids 16: 1566-1568.
38. Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M (2008) Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 47: 441-448.
39. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N (2007) Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 45(8): 1093-101.
40. Vo TT, Ledergerber B, Keiser O, Hirschel B, Furrer H, et al. (2007) Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008, 197: 1685-1694.
41. Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, et al. (2007) Discontinuation and modification of highly active antiretroviral therapy in HIVinfected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr 45: 218-223.